Jan 11, 2007 — FDA approval last week of Anthera’s Investigational New Drug (IND) application for its lead ...
Pharmaceuticals
This channel includes news and new technology innovations for cardiovascular pharmaceutics. This includes antiplatelet agents, anticoagulation drugs, INR testing, NOAC, OAC, IV administered drugs such as Heprin, and dual antiplatelet therapy.
Jan. 5, 2007 — An announcement from AstraZeneca is expected soon about the company’s experimental heart drug AGI ...
A review by physicians at Tulane University School of Public Health and Tropical Medicine shows that Vitamin B12 ...
Heartwire cites results of a new study finding that current heart-failure performance measures, with the exception of ...
Taking anti-platelet medication longer than current recommendations may lower heart attack or death risks for patients ...
The FDA was notified on Dec. 2 that Pfizer will suspend a large, Phase 3 trial evaluating the investigational ...
CV Therapeutics has announced it will file a new drug application to the FDA for its regadenoson agent in mid-2007 ...
The Society for Cardiac Angiography and Interventions (SCAI) has extended the abstract deadline for its 30th Annual ...
Houston based ThromboVision, Inc. has won the first annual Michael E. DeBakey Life Science Award, which carries a ...
An aspirin a day really does keep heart attack and stroke away for women, yet fewer than half of American women ...
San Francisco-based McKesson announced it has agreed to purchase Per-Se Technologies, Alpharetta, Ga., in a deal ...
Washington University surgeons at Barnes-Jewish Hospital, St. Louis, began training at UMC in Tucson on Nov. 2 to become ...
Results from the Phase II MEND-CABG study — which looked at demonstrated the clinical benefits of MC-1 in reducing ...
Hospitals and other medical facilities across the state of Washington will receive $1 million in grant money allocated ...
The FDA has approved NitroMist (Nitroglycerin Lingual Aerosol) for acute relief of an attack or acute prophylaxis of ...